Antiretroviral drug resistance among antiretroviral-naïve persons with recent HIV infection in Thailand

HIV Medicine

Volumn 9, Issue 5, 2008, Pages 322-325

  Apisarnthanarak, Anucha ^a   Jirayasethpong, T ^b   Sa Nguansilp, C ^c   Thongprapai, H ^c   Kittihanukul, C ^c   Kamudamas, A ^a   Tungsathapornpong, A ^a   Mundy, L M ^d  

^a THAMMASAT UNIVERSITY HOSPITAL   (Thailand)

^b Rajvithee Hospital   (Thailand)

^c Health Concept International Ltd ^*  (Thailand)

^d SAINT LOUIS UNIVERSITY   (United States)

Author keywords

Antiviral drug resistance; Drug na ve; HIV; Recent infection; Thailand

Indexed keywords

ANTIRETROVIRUS AGENT; GENERIC DRUG; GPOVIR; LAMIVUDINE PLUS NEVIRAPINE PLUS STAVUDINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ANTIVIRAL RESISTANCE; ARTICLE; CONTROLLED STUDY; DRUG EXPOSURE; DRUG TREATMENT FAILURE; FEMALE; HIGH RISK PATIENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; MEDICAL DOCUMENTATION; MUTATIONAL ANALYSIS; PATIENT COMPLIANCE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK REDUCTION; SAFE SEX; THAILAND;

ADOLESCENT; ADULT; ANTI-RETROVIRAL AGENTS; CONDOMS; CROSS-SECTIONAL STUDIES; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; PREGNANCY; PROSPECTIVE STUDIES; RNA, VIRAL; SEXUAL BEHAVIOR; THAILAND; VIRAL LOAD;

EID: 42149172650     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2008.00562.x     Document Type: Article

References (18)

1. Smith D, Moini N, Pesano R et al. Clinical utility of HIV standard genotyping among antiretroviral-naïve individuals with unknown duration of infection. Clin Infect Dis 2007; 44: 456-458.
2. De Luca A, Weidler J, Di Giambenedetti S et al. Association of HIV-1 replication capacity with treatment outcomes in patients with virologic treatment failure. J Acquir Immune Defic Syndr 2007; 45: 411-417.
3. Seyler C, Adjé-TouréC, Messou E et al. Impact of genotypic drug resistance mutations on clinical and immunological outcomes in HIV-infected adults on HAART in West Africa. AIDS 2007; 21: 1157-1164.
4. Little SJ, Holte S, Routy JP et al. Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med 2002; 347: 385-394.
5. Little SJ. Is transmitted drug resistance in HIV on the rise? It seems so. BMJ 2001; 322: 1074-1075.
6. Grubb JR, Singhatiraj E, Mondy K, Powderly WG, Overton ET. Patterns of primary antiretroviral drug resistance in antiretroviral-naïve HIV-1-infected individuals in a midwest university clinic. AIDS 2006; 20: 2115-2116.
7. Yerly S, Vora S, Rizzardi P et al. Acute HIV infection: Impact on the spread of HIV and transmission of drug resistance. AIDS 2001; 15: 2287-2292.
8. UK Collaborative Group on Monitoring the Transmission of HIV Drug Resistance. Analysis of prevalence of HIV-1 drug resistance in primary infections in the United Kingdom. BMJ 2001; 322: 1087-1088.
9. Briones C, Pérez-Olmeda M, Rodriguez C, del Romero J, Hertogs K, Soriano V. Primary genotypic and phenotypic HIV-1 drug resistance in recent seroconverters in Madrid. J Acquir Immune Defic Syndr 2001; 26: 145-150.
10. Sungkanuparph S, Manosuthi W, Kiertiburanakul S, Piyavong B, Chumpathat N, Chantratita W. Options for a second-line antiretroviral regimen for HIV type 1-infected patients whose initial regimen of a fixed-dose combination of stavudine, lamivudine, and nevirapine fails. Clin Infect Dis 2007; 44: 447-452.
11. Sukasem C, Churdboonchart V, Chasombat S et al. Surveillance of genotypic resistance mutations in chronic HIV-1 treated individuals after completion of the National Access to Antiretroviral Program in Thailand. Infection 2007; 35: 81-88.
12. Sutthent R, Arworn D, Kaoriangudom S et al. HIV-1 drug resistance in Thailand: Before and after National Access to Antiretroviral Program. J Clin Virol 2005; 34: 272-276.
13. Kitkungvan D, Apisarnthanarak A, Plengpart P et al. Fever of unknown origin in patients with human immunodeficiency virus infection in Thailand: An observation study and review of the literature. Int J STD AIDS 2008, in press.
14. Janssen RS, Satten GA, Stramer SL et al. New testing strategy to detect early HIV-1 infection for use in incidence estimates and for clinical and prevention purposes. JAMA 1998; 280: 42-48.
15. Grant RM, Hecht FM, Warmerdam M et al. Time trends in primary HIV-1 drug resistance among recently infected persons. JAMA 2002; 288: 181-188.
16. Kuritzkes DR, Grant RM, Feorino P et al. Performance characteristics of the TRUGENE HIV-1 genotyping kit and the Opengene DNA sequencing system. J Clin Microbiol 2003; 41: 1594-1599.
17. Johnson VA, Brun-Vezinet F, Clotet B et al. Update of the drug resistance mutations in HIV-1: Fall 2005. Top HIV Med 2005; 13: 125-131.
18. Sax PE, Islam R, Walensky RP et al. Should resistance testing be performed for treatment-naïve HIV-infected patients? A cost-effectiveness analysis. Clin Infect Dis 2005; 41: 1316-1323.